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N’-Mcthylnicotinamide and nicotinamide, which decreased invitro ADP-ribosylation of nuclear proteins and/or cellular NAD’ content, selectively 
increased the basal expression of the rat growth hormone (GH) gene promoter and its response to triiodothyronimz (T3). This increase was not 
found wllcn the thyroid hormone response lement (TRE) was deleted from the promoter. Transfection with an expression vector for the T3 receptor 
inhibited basal activity of the TRE-containing promoter and repressed the slimulatory dEct of N’-methylnicotinamide. The addition of hormone 
relieved this inhibition and enhanced transcription above levels found in the absence ofthe transfected receptors. These results uggest amodulatory 
role of ADP-ribosylation in hormonal regulation of gene expressio:~. 
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1 a INTRODUCTION 
Nuclear proteins are subjected to covalent post-trans- 
lational modifications which cause changes in the struc- 
ture of nucleosomes and influence transcriptional regu- 
lation. It has been suggested that ADP-ribosylation of 
chromosomal proteins erves as a negative regulator for 
gene expression [I ,2]. A decrease in ADP-ribosylation 
has been shown to correlate with an increase in non- 
specific RNA synthesis [l], but it can also influence the 
expression of specific genes [2,3]. Kimura et al. [3] have 
shown that compounds that decrease ADP-ribosylation 
specifically increase growth hormone (GH) synthesis 
and the level of GH-mRNA in cultured pituitary GH3 
cells. The expression of the GH gene is under hormonal 
control and those compounds also potentiate the induc- 
tion caused by the thyroid hormone triiodothyronine 
(T3) [3]. Additionally, we have shown that T3 alters 
ADP-ribosylation of chromatin proteins in pituitary 
GHI cells [4] and Tanuma et al. [2] have described a 
similar effect for glucocorticoid hormones in mammary 
cells suggesting a modulatory role of this modification 
on hormonal regulation of gene expression. 
The 5’ flanking region of the rat OH gene contains 
elements mediating pituitary-specific expression and re- 
sponse to hormonal signals [S]. Two cell-specific ele- 
ments located from -95 to -65 and from - I37 to - 107 
in the gene are binding sites for the pituitary-specific 
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transcription factor GHF-1 [6], a homeodomain protein 
also known as Pit-l [7]. Thyroid hormone action is 
mediated by binding to nuclear eceptors, the product 
of c-erb.4 proto-oncogenes, which function as ligand- 
inducible transcriptional enhancer factors [8,9]. -We and 
others have previously shown that sequences between 
-209 and - I46 of the rat GI-I gene function as a thyroid 
hormone responsive lement (TRE) and mediate thy- 
roid hormone stimulation [lo-121. In this study we have 
investigated the effect of nicotinamide analogs that in- 
hibit ADP-ribosylation, alone or in combination with 
T3, on hormone-dependent and -independent transcrip- 
tion of the GH gene promoter. 
2. MATERIALS AND METHODS 
The -1441X-CAT and -530GHmCAT constructs contain 144 or 
530 base pairs, respectively, of 5’ flanking DNA of the rat GH gene 
fused to cbloramphenicol acetyltransferase (CAT) gene [l2]. In an- 
other GHCAT construct he fragment -23W530, has been ligated 
upstream of a minimal GH gene promoter (-104/+ll) [I21 . The 
GHF-I CAT plasmid contains 400 base pairs of the rat GHF-1 gene 
ligated to CAT [13], and in the RSV-CAT plasmid the CAT gene is 
under control of enhancer and promoter sequences of the Roux sar- 
coma virus long terminal repeat. A vector expressing the chick thyroid 
hormone receptor wbh under control of the RSV promoier has 
been previously described [14]. 
Gl-I I cells were cultured as previously described [I51 in DMEM 
medium containing IO%,AGl x 8 resin-charcoal stripped newborn 
calf serum [I61 to ensure cellular depletion of thyroid hormone. The 
cells were iransfectcd by electroporation asdescribed [12,14,15]. IOyg 
of the reporter plasmids were mixed with 20-40 million cells and 
exposed to a high voltage pulse (I 70-200 V, 960 pF). The cells from 
each electroporation were split in different culture plates and incu- 
bated for 48 h with the compounds indicated. At this time a maximal 
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Fig. I. (Left) GHI cells were transfcctPA with the reporter plasmid -530GH-CAT and incubated for 48 h before determination of CAT activity 
in control medium (C) or in medium containing IO mM K-mahylnicotinamide (MN) or 25 mM nicotinamide (N) in the absence (strippeo bars) 
or presence (black bars) of 1 nM triiodothyronine (T3). (Right) T3 receptor levels. intracellular NAD content and [‘H]ADP-ribase incorporation 
into isolated nuclei were determined in triplicate cultures of csn trol cells(C) and cells treated with the same concentrations of N’-mcthylnicotinamidc 
(MN) or nicolindmidc ’i+Ij ijr 24 h. The data are mrdn i SD. 
CAT response was found. Each treatment was performed induplicate 
cultures that normally showed less than 5-10% variation in CAT 
activity. CAT activity was determined, as previously described [12,15], 
by incubation of the cell extracts (15-50 pg) with [‘JC]cblorampheni- 
co]. The unreactrd and acetylated [‘JC]chloramphcnicol were sepa- 
rated by thin layer chromatography, identified by auturzdiography 
and quantitated. 
The level oTT3 rbxeptors was detcrmincd by incubation of the cell 
monolayers in serum-fret medium for 90 min with 0.8 nM [‘?“I]T3 
[16,17]. This concentration of T3 gives an estimate of the total levels 
of receptor since it binds to more than 90% of the thyroid hormone 
receptor population. 
2.4. ADP-ribosylariotr in isolated nuclei 
ADP-ribosylation assays were carried out US previously described 
[IS] by incubation for I5 min at 37’C in 0.5 ml or 0.1 M Tris-HCI, 
2 mM MgC&, I mM dithiothreitol, pH 7.9, containing 0.25 PCi 
[‘H]NAD+ and 0.5 mM unlabclcd NAD. The nuclei were washed and 
the nuclear material precipitated with 18% trichloroacetic n id (TCA). 
The TCA-insoluble material was dissolved in 0.4 N NaOH and an 
aliquot was used to analyrc [‘H]ADP-ribosc incorporation. Another 
aliquot was saved for determination of proteins [I9])]. 
2.5. Dctcrrnimtion of eeihdar NAD’feveis 
0.5 N pcrchloric acid extracts of GM1 cells [I81 was assayed for 
NAD using a spectrophotomelric technique [20]. 
3. RESULTS 
Fig. 1 (right) shows that incubation with 10 mM N’- 
methylnicotinamide decreased by approximately 50% 
ADP-ribose incorporation into nuclear proteins and re- 
duced by more than 70% the cellular levels of NAD’, 
the substrate for the reaction of ADP-ribosylation. This 
co_mpour?d also produced a significant decrease of thy- 
roid hormone receptor levels (more than 50%). Higher 
concentrations of N’-methylnicotinamide id not pro- 
duce further decreases (not shown). Nicotinamide 
(25 mM) also inhibited ADP-ribose incorporation and 
did not decrease but rather increased NAD’ levels, 
probably as a consequence of its reduced utilization for 
ADP-ribosylation. To examine the influence of the in- 
hibitory compounds on GM gene transcription, tran- 
sient gene expression was performed using a -530GH- 
CAT construct. Fig. 2 (left) shows that incubation with 
IV’-methylnicotinamide increased activity of the GH 
promoter by more than 3-fold and potentiated the ac- 
tion of T3. The combination of T3 and IV’-methylnicoti- 
namide caused an almost IO-fold increase in CAT activ- 
ity. Nicotinamide was less effective in increasing basal 
promoter expression by 2-fold, but enhanced the re- 
sponse to T3. As shown in the figure both compounds 
potentiated the effect of T3 on the GM gene and signif- 
icantly reduced the number of its nuclear receptors. 
The fragment of the GM gene promoter in the 
-530GH-CAT plasmid includes the TRE which medi- 
ates regulation by the T3 receptors [lo-121. To examine 
whether the increased activity caused by the inhibitors 
of ADP-ribosylation was dependent on the presence of 
the TRE, the effect of N’-methylnicotinamide on the 
expression of a plasmid in which the sequences between 
-104/-236 that contain the TRE have been deleted was 
also examined. Fig. 2 compares the effect of T3 and 
IV-methylnicotinamide on the -530GI-LCAT and the 
-530(.4- 104/-236)GH-CAT plasmids. The stimulatory 
effect on the GH gene promoter was not found in the 
absence of the TRE since neither compound increased 
significantly CAT activity from the later construct. Sim- 
ilar results were obtained with a - 144GHXAT plasmid 
since neither T3 nor nicotinamide analogs enhanced its 
activity, thus showing that the sequences -i37i-iO7 do 
not mediate the enhanced CAT activity by IV-methyl& 
cotinamide. 
43 
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Fig. 2. CAT activity was determined in GHI cells transfected with the constructs indicated in the top of the figure and incubated for 48 h with 
1 nM triiodothyronine (T3), IO mM N-mcthylnicotinamide (MN) or the combination of both. 
Because the expression of the GH gene depends on 
the binding of the transcription factor GHF-1 to its 
cognate sites [6,7], we examined the possibility that the 
stimulatory effect of N’-methylnicotinamide could be 
due to increased GHF-I expression. For this purpose, 
GHl cells were transfected with a reporter plasmid con- 
taining the GHF-I promoter. Fig. 2 also shows that 
N’-methylnicotinamide did not increase GHF-I-CAT 
activity whether alone or in combination with T3. That 
the stimulatory effect of Iv”-methylnicotinamide s spe- 
cific for the GH gene promoter is also confirmed by the 
C 









finding that this compound did not alter the expression 
of a control plasmid containing the RSV promoter. T3 
did not affect RSV-CAT activity either. 
To examine the effect of over-expression of the thy 
roid hormone receptor on the response to T3 and N’- 
methylnicotinamide, the -530GHCA’T plasmid was 
transfected alone (Fig. 3A) or co-transfected with an 
expression vector encoding the receptor (Fig. 3B). The 
vector contains the cDNA sequences of the thyroid 
hormone receptor c-erbAa under control of the RSV 
promoter. Over-expression of c-&A, in the absence of 
Fig. 3. The cells were transl’ectecl with the -530GH-CAT reporter plnsrnid alone (panel A) or in combination with Il.J,uug of a c=erbn expression 
vector (panel B) and treated for 45 h with I nM T3 or 10 mM A”-mcthylnicotinamidc. Autoradiographs showing the conversion of [“Clchloram- 
phenicol o its acetylated forms arc shown in the lert panels and CAT activity expressed as fold increase above the levels found in controls (C) 
is illustrated in the right panels. 
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hormone, resulted in a significant decrease of the basal 
activity of the TRE-containing promoter. The addition 
of hormone relieved this inhibition and enhanced tran- 
scription above levels found in the absence of the trans- 
fected receptors. The right panels in Fig. 3 show that the 
response to T3, expressed as fold-induction over the 
corresponding basal levels, increased from approxi- 
mately 3-fold to almost SO-fold in the cells transfected 
with c-erbA. Additionally, the transfected receptor e- 
pressed the stimulatory effect of N’methylnicoti- 
namidc, decreasing from a S-fold induction in the ab- 
sence of exogenous receptor to a less than 1 J-fold in- 
duction, after over-expression of the receptor. Again, 
this inhibition was overcome by the ligand: CAT activ- 
ity increased by more than SO-fold in receptor-trans- 
fected cells treated with T3 plus Iv’-mcthylnicotinamide. 
4. DISCUSSION 
Our results show that the increase of GH synthesis 
produced by nicotinamide analogs [3] occurs at the 
transcriptional level and can be attributed to enhanced 
expression of the GH gene. These compounds pecifi- 
cally increased basal and thyroid hormone-induced ex- 
pression of the GH gene promoter without affecting 
transcription from another reporter gene driven by a 
CCIiltrOl promoter. 
In agreement with previous results in pituitary cells 
[3] we fmd that nicotinamide and N’-methylnicoti- 
namide decrease in vitro ADP-ribose synthetase activity 
and/or decrease the cellular concentration of NAD’ the 
substrate for ADP-ribosylation. Since this modification 
produces conformational changes in chromatin [2 I], ni- 
cotinamide analogs might affect conformation of the 
GH promoter, facilitating the accessibility of regulatory 
proteins binding to tlzis promoter. In this respect, the 
element hat mediates thyroid hormone stimulation of 
the GH gene present at - 1671190 seems to be required 
for activation by nicotinamide and h”-methy!nicoti- 
namidc, since they do not enhance xpression of a GH 
promoter in which the TRE has been deleted. Addition- 
ally, these compounds were also effective in increasing 
the activity of an heterologous (MMTV) promoter con- 
taining the natural TRE of the rat GM gene (data not 
shown). These results suggest that a decrease in ADP- 
ribosylation may induce an altered configuration of the 
TRE, facilitating binding of the receptors to the modi- 
fied chromatin, This would be in agreement with the 
finding that induction of transfected genes by progester- 
one or glucocorticoid hormones, which bind to similar 
nuclear eceptors, depends on DNA topology [22]. 
The transcriptional effect of T3 on the GM gene is 
accompanied by a down-regulation of its receptor [l?]. 
Interestingly, both N’-methylnicotinamide and nicoti- 
namide stimulate basal expression and the response of 
the GH promoter to thyroid hormone and, concomi- 
tantly, cause a decrease in T3 receptor level in GH- 
producing cells. A possible interpretation of these find- 
ings is that the receptors could act as repressors in the 
absence of hormone. This is supported by the finding 
that transfection of an expression vector encoding the 
thyroid hormone receptor led to a ligand-independent 
inhibitory effect on transcription, suggesting that the 
receptors could act as specific repressors of GH gene 
expression in T3 deprived cells. A combination of re- 
pression of basal expression of TRE-containing pro- 
moters by unoccupied receptors and an increase in 
hormone-induced expression has been previously pro- 
posed [23-253. Furthermore, our data show that the 
over-expressed receptors are also able to counteract the 
stimulation caused by nicotinamide analogs, suggesting 
that the binding of hormone receptors could locally 
alter the chromatin structure and inhibit gene expres- 
sion. This inhibition is totally overcome when the thy- 
roid hormone binds to the receptor. A direct demon- 
stration that chromatin structural changes occur after 
glucocorticoid hormone administration and receptor 
binding has been reported by others [2G]. 
The precise molecular mechanism of transcriptional 
control by the thyroid hormone receptor is not known, 
but it is assumed that occupancy of the receptor by the 
ligand somehow facilitates the access of other transcrip- 
tion factors to the regulated promoter which stimulates 
the level of gene expression. As far as the GM gene is 
concerned, binding of GHF-1 to its cognate sites in the 
promoter is required for its basal expression in a cell- 
specific manner [6,7]. However, the stimulatory action 
of nicotinamide analogs does not involve an increase in 
GHF-1 since they did not stimulate xpression of the 
TRE-deleted GH promoter which contains a GHF-1 
binding site, or the activity of the GHF-1 promoter. 
Whether the treatment with these agents that decrease 
ADP-ribosylation enhance the functional cooperation 
of the receptors with GHF- 1, or facilitate its interaction 
with other still unidentified components of the tran- 
scriptional machinery remains to be established. 
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